As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

We came across a bullish thesis on Sana Biotechnology, Inc. (SANA) on wallstreetbets Subreddit Page by Intrepid_Web5454. In ...

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP ... preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 45.04% ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology ... preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP ... Early clinical data from Phase 1 trials and preclinical data published in peer-reviewed journals demonstrate across ...

Sana Biotechnology (NASDAQ ... It also helps that the company has fresh clinical trials on the horizon and a patent portfolio that might attract partnerships. Time will tell whether Sana can ...

(MENAFN- GlobeNewsWire - Nasdaq) First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP ... Early clinical data from Phase 1 trials and preclinical data published in peer-reviewed journals ...